Search research articles
Contact Us
Filters
Showing results (151-160 of 173) with videos related to
Page
of 18
Sort By:
Biomedicines
|
March 29, 2023
Prognostic Factors of Long-Term Outcomes after Primary Chemo-Radiotherapy in Non-Metastatic Anal Squamous Cell Carcinoma: An International Bicentric Cohort
Soledad Iseas, Diego Prost, Sarah Bouchereau, et al.
Therapeutic Advances in Medical Oncology
|
November 20, 2024
SUNLAND: a randomized, double-blinded phase II GERCOR trial of sunitinib versus placebo and lanreotide in patients with advanced progressive midgut neuroendocrine tumors
Pascal Hammel, Denis Smith, Pauline Afchain, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
July 9, 2025
Sunitinib as Second-Line Treatment in Advanced Intrahepatic Cholangiocarcinoma: Results From the SUN-CK GERCOR Phase II Trial
Louis Gros, Mohamed Bouattour, Clément Dumont, et al.
Oncotarget
|
August 11, 2016
Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib
Maria Serova, Annemilaï Tijeras-Raballand, Celia Dos Santos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 2, 2013
Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial
Ann-Lii Cheng, Yoon-Koo Kang, Deng-Yn Lin, et al.
Cancers
|
September 23, 2022
Targeting the Tumor Microenvironment through mTOR Inhibition and Chemotherapy as Induction Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma: The CAPRA Study
Diane Evrard, Clément Dumont, Michel Gatineau, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 17, 2023
Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours
Jorge Hernando, Maria Roca-Herrera, Alejandro García-Álvarez, et al.
Targeted Oncology
|
November 10, 2020
Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors
Jean-Pierre Delord, Antoine Italiano, Ahmad Awada, et al.
Journal of Neuroendocrinology
|
October 20, 2021
ENETS standardized (synoptic) reporting for molecular imaging studies in neuroendocrine tumours
Rodney J Hicks, Clarisse Dromain, Wouter W de Herder, et al.
Targeted Oncology
|
November 19, 2020
Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial
Céleste Lebbé, Antoine Italiano, Nadine Houédé, et al.
Page
of 18
Search research articles
Search
Showing results (151-160 of 173) with videos related to
Sort By:
Page
of 18
Biomedicines
|
March 29, 2023
Prognostic Factors of Long-Term Outcomes after Primary Chemo-Radiotherapy in Non-Metastatic Anal Squamous Cell Carcinoma: An International Bicentric Cohort
Soledad Iseas, Diego Prost, Sarah Bouchereau, et al.
Therapeutic Advances in Medical Oncology
|
November 20, 2024
SUNLAND: a randomized, double-blinded phase II GERCOR trial of sunitinib versus placebo and lanreotide in patients with advanced progressive midgut neuroendocrine tumors
Pascal Hammel, Denis Smith, Pauline Afchain, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
July 9, 2025
Sunitinib as Second-Line Treatment in Advanced Intrahepatic Cholangiocarcinoma: Results From the SUN-CK GERCOR Phase II Trial
Louis Gros, Mohamed Bouattour, Clément Dumont, et al.
Oncotarget
|
August 11, 2016
Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib
Maria Serova, Annemilaï Tijeras-Raballand, Celia Dos Santos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 2, 2013
Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial
Ann-Lii Cheng, Yoon-Koo Kang, Deng-Yn Lin, et al.
Cancers
|
September 23, 2022
Targeting the Tumor Microenvironment through mTOR Inhibition and Chemotherapy as Induction Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma: The CAPRA Study
Diane Evrard, Clément Dumont, Michel Gatineau, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 17, 2023
Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours
Jorge Hernando, Maria Roca-Herrera, Alejandro García-Álvarez, et al.
Targeted Oncology
|
November 10, 2020
Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors
Jean-Pierre Delord, Antoine Italiano, Ahmad Awada, et al.
Journal of Neuroendocrinology
|
October 20, 2021
ENETS standardized (synoptic) reporting for molecular imaging studies in neuroendocrine tumours
Rodney J Hicks, Clarisse Dromain, Wouter W de Herder, et al.
Targeted Oncology
|
November 19, 2020
Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial
Céleste Lebbé, Antoine Italiano, Nadine Houédé, et al.
Page
of 18